Sinovac Biotech announced the launch of the 2008-2009 version of its seasonal flu vaccine, Anflu®. Anflu is the only split influenza vaccine produced without preservatives in China. Sinovac said it would market the vaccine to adults. Last year, Sinovac signed a co-promotion agreement with GlaxoSmithKline under which Sinovac was responsible for marketing Anflu to children, while GSK took over the duty for adults. More details...
Stock Symbols: (AMEX: SVA) (NYSE: GSK)
Sorry... this feature or article is only available to subscribers.